Mok 2009 |
Randomized |
154 |
All histologies, |
Arm A (76 pts): |
34% |
28% |
Arm A: 35.5% |
Arm A: 6.9 m |
Arm A: 17.3 m |
(FASTACT) 26 |
Phase 2 |
|
previously untreated |
Gem, d 1 & 8 |
|
|
Arm B: 24.4% |
Arm B: 5.5 m |
Arm B: 17.7 m |
|
|
|
|
Cis or Carbo, day 1 |
|
|
|
|
|
|
|
|
|
Erlotinib, d 15-28 |
|
|
P = 0.12 |
P = 0.002 |
P: ns |
|
|
|
|
Cycle q 4 weeks |
|
|
|
|
|
|
|
|
|
Arm B (78 pts): |
|
|
|
|
|
|
|
|
|
as above, placebo |
|
|
|
|
|
|
|
|
|
instead of Erlotinib |
|
|
|
|
|
|
|
52 |
As above, |
Arm A (24 pts) |
100% |
49% |
Arm A: 45.8% |
Arm A: 11.1 m |
Not reached |
|
|
|
neversmokers |
Arm B (28 pts) |
|
|
Arm B: 32.1% |
Arm B: 6.4 m |
|
|
|
|
|
Treatment as above |
|
|
P: not |
P = 0.002 |
|
|
|
|
|
|
|
|
reported |
|
|
Hirsch 2011 27 |
RandomizedPhase 2 |
143 |
Positive for EGFRprotein expressionand/or with highEGFR gene copynumber, previouslyuntreated |
Arm A (71 pts):Pacli d 1Carbo d 1Erlotinib d 2 - 15Cycle q 3 weeksArm B (72 pts):Erlotinib |
28% |
10% |
Arm A: 22.4%Arm B: 11.6%P = ns |
Arm A: 4.6 mArm B: 2.7 mP = ns |
Arm A: 11.4 mArm B: 16.7 mP = ns |
Aerts 2012(NVALT 10) 28 |
RandomizedPhase 2 |
231 |
All histologiesProgression afterplatin-basedchemotherapy |
Arm A (115 pts):ErlotinibArm B (116 pts):Doce or Pem, d 1Erlotinib, d 2 - 16Cycle q 3 weeks |
7% |
4% |
Arm A: 7%Arm B: 13%P = 0.03 |
Arm A: 4.9 mArm B: 6.1 mP = 0.11 |
Arm A: 5.5 mArm B: 7.8 mP = 0.01 |
Lee 2013 29 |
RandomizedPhase 2 |
240 |
Non-squamous,never-smokers,Progression after 1stline chemotherapy |
Arm A (78 pts):Pem d 1Erlotinib d 2 - 14,Cycleq 3 weeksArm B (82 pts):Erlotinib continuouslyArm C (80 pts):Pem d 1,Cycle q 3weeks |
100% |
56% |
Arm A: 44.7%Arm B: 29.3%Arm C: 10.0%P = 0.001 |
Arm A: 7.4 mArm B: 3.8 mArm C: 4.4 mP = 0.003 |
Arm A: 20.5 mArm B: 22.8 mArm C: 17.7mP = 0.19 |
Wu Y-L 2013(FASTACT 2) 30 |
RandomizedPhase 3 |
451 |
All histologies,previously untreated |
Arm A (226 pts):Gem, d 1 & 8Cis or Carbo, d 1Erlotinib, d 15-28Cycle q 4 weeksArm B (225 pts):as above, placeboinstead of Erlotinib |
49% |
39% |
Arm A: 44%Arm B: 16%P < 0.0001 |
Arm A: 7.6 mArm B: 6.0 mP < 0.0001 |
Arm A: 18.3 mArm B: 15.2 mP = 0.04 |
|
|
97 |
As above, subgroupwith activating EGFRmutations |
Arm A (49 pts):Arm B (48 pts):Treatment as above |
Notseparatelyreported |
100% |
Arm A: 84%Arm B: 15%P < 0.0001 |
Arm A: 16.8 mArm B: 6.9 mP < 0.0001 |
Arm A: 31.4 mArm B: 20.6 mP = 0.009 |
Auliac 2014 31 |
RandomisedPhase 2 |
147 |
EGFR wild-type orunknownProgression after 1stline chemotherapy |
Arm A (73 pts):Doce, d 1Erlotinib, d 2 - 16Cycle q 3 weeksArm B (74 pts):Doce, d 1 |
7.5% |
4% |
Arm A: 4.4%Arm B: 1.4%P = ns |
Arm A: 2.2 mArm B: 2.5 mP = ns |
Arm A: 6.5 mArm B: 8.3 mP = ns |
Karavasilis2014 32 |
RandomizedPhase 2 |
50 |
All histologiesPreviously untreated |
Arm A (25 pts):Doce, d 1Erlotinib, d 9 - 20Arm B (25 pts):Doce, d 1Erlotinib, d 3 - 14ycle q 3 weeks |
10% |
11% |
Arm A: 24%Arm B:12% |
Arm A: 2.9 mArm B: 4.2 m |
Arm A: 9.9 mArm B: 10.8 m |
Mok 2014 33 |
RandomizedPhase 2 |
123 |
Unselected,progression afterplatin-based ChT |
Arm A (63 pts):Eribulin mesylate, d1Erlotinib, d 2-16Cycle q 3 weeksArm B (60 pts):Eribulin mesylate, d 1and 8Erlotinib, d 15-28Cycle q 4 weeks |
24% |
28% |
Arm A: 13%Arm B:17%P = ns |
Arm A: 3.5 mArm B: 3.8 mP = ns |
Arm A: 7.6 mArm B: 8.5 mP = ns |
Yu 2014 34 |
RandomizedPhase 2 |
117 |
Non-squamous,previously untreated |
Arm A (58 pts):Pem, d 1Cis or Carbo, d 1Gefitinib, d 3 – 16Cycle q 3 weeksArm B (57 pts):As above, no Gefitinib |
58% |
40% |
Arm A: 50.0%Arm B: 47.7%P = ns |
Arm A: 7.9 mArm B: 7.0 mP = ns |
Arm A: 25.4mArm B: 20.8 mP = ns |
|
|
32 |
As above, subgroupwith activating EGFRmutations |
Arm A: 14 ptsArm B: 18 ptsTreatment as above |
Notseparatelyreported |
100% |
Arm A: 76.9%Arm B: 50.0%P = 0.13 |
Arm A:Not reachedArm B: 14.0 mP = 0.017 |
Not reached |
Choi 2015 35 |
RandomizedPhase 2 |
90 |
NSCLC, EGFR wild.type or unknownPS 0 – 2, previouslyuntreated |
Arm A (44 pts):Pem, d 1 Carbo, d 1Gefitinib, d 2 – 15Cycle q 3 weeks x 4Maintenance GefitinibArm B (46 pts):As Arm A, no Gefitinib |
10% |
10% |
Arm A: 41.9%Arm B: 39.5%P = ns |
Arm A: 4.1 mArm B: 4.1 mP = ns |
Arm A: 9.3 mArm B: 10.5 mP = ns |
Juan 2015 36 |
RandomizedPhase 2 |
68 |
All histologiesProgression afterplatin-basedchemotherapy |
Arm A (33 pts):Doce q 3 weeksErlotnib, d 2 – 16Arm B (35 pts):Erlotinib continuously |
6% |
5% |
Arm A: 3%Arm B: 9%P = 0.19 |
Arm A: 3.0 mArm B: 2.1 mP = 0.19 |
Arm A: 7.5 mArm B: 5.2 mP = 0.19 |
Lu 2015 37 |
RandomizedPhase 3 |
219 |
Adenocarcinoma,EGFR unknown,non-smokers, noprogression after 2cycles of gem-carbo |
Arm A (109 pts):Gem, d 1 and 8Carbo, d 1Gefitinib d 15-25 andmaintenanceCycle q 4 weeks x 4Arm B (110 pts):As above, no Gefitinib |
100% |
72% |
Not reported |
Arm A: 10 mArm B: 4.4 mP = 0.001 |
Not reported |
Michael2015 38 |
RandomizedPhase 2 |
54 |
All histologiesPS 2 or elderlyPreviously untreated |
Arm A (28 pts):Gem d 1 and 8Erlotinib days 15 – 28Cycle q 4 weeksArm B (26 pts):Gem d1 and 8Cycle q 4 weeks |
15% |
12% |
Arm A: 6%Arm B: 23%P: ns |
Arm A: 2.5 mArm B: 1.9 mP: ns |
Arm A: 3.9 mArm B: 4.4 mP: ns |
Han 2016 39 |
RandomizedPhase 2 |
121 |
Adenocarcinoma,EGFR mutant,previously untreated |
Arm A (40 pts):Pem, d1 +maintenanceCarbo, d1 for ≤ 6 cyclesGefitinib, d 5-21 +maintenanceCycle q 4 weeksArm B (40 pts):As above, no GefitinibArm C (41 pts):Gefitinib alone |
Notreported |
100% |
Arm A: 82.5%Arm B: 32.5%Arm C: 65.9%P: 0.04 |
Arm A: 18.8 mArm B: 5.7 mArm C: 12.0 mP: notreported |
Not reached |
Lara 2016(SWOGS0709) 40 |
RandomizedPhase 2 |
59 |
PS 2, Proteomics:VeriStrat-goodstatus, previouslyuntreated |
Arm A (33 pts):ErlotinibArm B (26 pts):Pacli d 1Carbo d 1Erlotinib d 2 – 16Cycle q 3 weeks x 4Maintenance Erlotinib |
20% |
20% |
Arm A: 6%Arm B: 23%P = 0.06 |
Arm A: 1.6 mArm B: 4.6 mP = 0.06 |
Arm A: 6.0 mArm B: 11.0 mP = 0.27 |
Li 2016 41 |
RandomizedPhase 2 |
79 |
Predominantly non-squamousProgression after 1stline chemotherapy |
Arm A (27 pts):Pem d 1Cycle q 3 weeksArm B (52 pts):Pem d 1Erlotinib d 2 – 17Cycle q 3 weeks |
Notreported |
19% |
Arm A: 10%Arm B: 29%P = 0.17 |
Arm A: 2.9 mArm B: 4.7 mP = 0.26 |
Arm A: 8.3 mArm B: 9.7 mP = 0.28 |
Lee 2016 42 |
RandomizedPhase 2 |
76 |
Adenocarcinoma,neversmokers,Previously untreated |
Arm A (39 pts):Pem d1Carbo d 1Gefitinib d 5 - 18 +maintenanceCycle q 3 weeks xmax 9Arm B (37 pts):As arm A, placeboinstead of GefitinibAt progression: Gefitinibfor arm B |
100% |
42% |
Arm A: 79.5%Arm B: 51.4%P = 0.01 |
Arm A: 12.8 mArm B: 7.0 mP = 0.009 |
Arm A: 29.2 mArm B: 20.4 mP = 0.15 |
|
|
29 |
As above, EGFRmutant |
Arm A: 15 ptsArm B: 14 ptsTreatment as above |
100% |
100 |
Arm A: 86.7%Arm B: 42.9%P = 0.01 |
Arm A: 13.3 mArm B: 7.8 mP = 0.08 |
Arm A: 26.6 mArm B: 22.2 mP = ns |
|
|
37 |
As above,EGFR wt |
Arm A: 22 ptsArm B: 15 ptsTreatment as above |
100% |
0 |
Arm A: 72.7%Arm B: 57.1%P = ns |
Arm A: 6.6 mArm B: 6.6 mP = 0.08 |
Arm A: 29.2 mArm B: 15.9 mP = 0.09 |
Yoon 201643 |
RandomizedPhase 2 |
87 |
Non-squamousProgression after 1stline chemotherapy |
Arm A (57 pts):Pem d 1Afatinib d 2 – 15Arm B (30 pts):Pem d 1 |
31% |
31% |
Arm A: 31.8 %Arm B: 13.3%P = 0.074 |
Arm A: 5.7 mArm B: 2.9 mP = 0.16 |
Arm A: 12.1 mArm B: 15.6 mP = 0.245 |